Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.

@article{Ravandi2012PrognosticSO,
  title={Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin.},
  author={Farhad Ravandi and Keyur Pravinchandra Patel and Rajyalakshmi Luthra and Stefan H. Faderl and Marina Y Konopleva and Tapan M Kadia and Mark Brandt and Sherry A. Pierce and Steven M. Kornblau and Michael Andreeff and Xuemei Wang and Guillermo Garcia-Manero and Jorge E. Cortes and Hagop M Kantarjian},
  journal={Cancer},
  year={2012},
  volume={118 10},
  pages={2665-73}
}
BACKGROUND IDH1 and IDH2 gene mutations are novel, recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia (AML). METHODS Among 358 patients with AML treated on 4 protocols using high-dose ara-C plus idarubicin induction, pretreatment samples were available for 170 (median age 53 years, [range, 17-73]; 96% ≤65) and were evaluated for IDH1R132, IDH2R172, and IDH2R140 mutations or the codon 105 single nucleotide polymorphism (SNP) in IDH1. RESULTS IDH1 and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
IDH aberrations and IDH1 codon 105 SNP occur in about 30% of younger patients with AML , mostly with diploid karyotype .
Among the patients with diploid karyotype and NPM1(mut ) FLT3(WT ) genotype , those with IDH1 or IDH2 mutations had an inferior outcome .
Among the patients with diploid karyotype and NPM1(mut ) FLT3(WT ) genotype , those with IDH1 or IDH2 mutations had an inferior outcome .
IDH aberrations and IDH1 codon 105 SNP occur in about 30% of younger patients with AML , mostly with diploid karyotype .
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
Among 358 patients with AML treated on 4 protocols using high - dose ara - C plus idarubicin induction , pretreatment samples were available for 170 ( median age 53 years , [ range , 17 - 73 ] ; 96% ≤65 ) and were evaluated for IDH1R132 , IDH2R172 , and IDH2R140 mutations or the codon 105 single nucleotide polymorphism ( SNP ) in IDH1 .
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high - dose cytarabine and idarubicin .
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
BACKGROUND . IDH1 and IDH2 gene mutations are novel , recurring molecular aberrations among patients with normal karyotype acute myeloid leukemia ( AML )
All Topics